Nine Diagnostics Wins Novo Nordisk Golden Ticket for LabCentral Residency

Nine Diagnostics, a leader in cutting-edge medical diagnostics, is honored to announce that it has been awarded the Novo Nordisk Golden Ticket for a residency at LabCentral, hosted by the Novo Nordisk Bio Innovation Hub. This incredible opportunity is a significant milestone for the company, reinforcing its commitment to improving healthcare through advanced technologies that enable faster, more personalized diagnostics.

The Golden Ticket award provides Nine Diagnostics with the resources and support to further develop its innovative AI-enabled nanosensor platform, designed to detect proteins and metabolites. By capturing real-time biological data from biological samples such as blood serum, the platform creates multidimensional health profiles by integrating clinical data with environmental and social factors. This approach ultimately aims to improve treatment effectiveness and accelerate diagnostic feedback loops.

“We are deeply honored and excited to receive this recognition from Novo Nordisk,” said Dr. Freddy T. Nguyen, MD, PhD, CEO and Co-Founder of Nine Diagnostics. “Being part of LabCentral’s vibrant and collaborative environment will allow us to accelerate the development of our platform and bring us one step closer to achieving our vision of functional precision medicine.”

This year’s competition was intense, with an impressive group of biotech and life sciences startups vying for the Golden Ticket. Alongside Nine Diagnostics, Lilium Therapeutics was also awarded a golden ticket, and both companies will soon begin their year-long journey at LabCentral. The award includes lab space, mentorship, and collaboration opportunities, all designed to foster innovation and support breakthroughs in healthcare.

Stanislav Piletsky, PhD, Research and Development at Nine Diagnostics, expressed his pride in the team’s achievement. “This Golden Ticket is a major stepping stone for us. It provides a unique opportunity to refine our technology and expand our impact, particularly in areas such as cancer diagnostics,” he said.

This opportunity marks a major turning point for Nine Diagnostics as it continues to push the boundaries of precision medicine. With the support of LabCentral, Novo Nordisk, and a community of innovators, Nine Diagnostics is poised to make a lasting impact on the future of medical diagnostics.

To learn more about Nine Diagnostics and its transformative approach to healthcare, visit ninediagnostics.xyz.

About Nine Diagnostics
The mission of Nine Diagnostics is to accelerate the path to the most effective treatment for the individual patient by actualizing on functional precision medicine. The founding team of clinician, scientists, engineers, innovators, and entrepreneurs came together to tackle some of healthcare’s largest problems in developing a breakthrough technology that could help detect diseases earlier, provide rapid feedback on treatment selection and effectiveness, and monitor disease recurrence or treatment resistance. We aim to provide a rapid feedback loop for therapy selection, dosing, frequency, and cadence, and guide decisions on combination therapies helping clinicians and therapeutic developers access earlier markers for treatment effectiveness and accelerating patients towards more effective treatments.

About The Bio Innovation Hub
The Novo Nordisk Bio Innovation Hub is a cross-disciplinary R&D unit located in Cambridge, MA. It fosters partnerships across the life sciences ecosystem to accelerate the development of therapies for cardiometabolic and rare diseases, working with biotech, academia, and healthcare innovators.

About LabCentral
LabCentral is a nonprofit launchpad that supports life sciences and biotech startups. Located in Cambridge, MA, LabCentral offers lab space, programming, and networking to help early-stage companies bring their innovations to market.